Search results
Results from the WOW.Com Content Network
Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. [10] Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. [10] Use during pregnancy may harm foetal development. [10]
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
New RSV vaccines are now available to help prevent serious infection in people over 60. Doctors explain the RSV vaccine and its side effects in older adults.
Behind the counter at your local gas station, convenience store, or bodega, tucked within the energy shots and flavored cigarillos, are a variety of male enhancement products like Rhino pills. You ...
Plus, how to manage them. For premium support please call: 800-290-4726 more ways to reach us
The core side effects of NSAAs such as gynecomastia, sexual dysfunction, and hot flashes occur at similar rates with the different drugs. [ 48 ] [ 49 ] Conversely, bicalutamide is associated with a significantly lower rate of diarrhea compared to flutamide.
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...